Oblique Therapeutics
Dr. Scherlund has extensive experience from the life science industry, from early development to product launch, working at both large and small size companies such as Astra Zeneca, RISE, APL, Moberg Pharma and Cadila Pharmaceuticals. Scherlund holds a Ph.D in Pharmaceutics from Uppsala University, and has wide-ranging leadership experience from different senior management positions, amongst project leadership, regulatory affairs as well as heading departments of pharmaceutical development and quality control.
Oblique Therapeutics
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic cancer.